Global Fermentation Engineering for Pharmaceutical Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Fermentation Engineering for Pharmaceutical Drugs Market Research Report 2024
Fermentation is a process used for cultivating micro-organisms or other organic material into important pharmaceuticals such as antibiotics, therapeutic proteins, enzymes and insulin. It is typically carried out in temperature-controlled tanks (fermenter) which require addition of nutrients at the correct concentration to maximize productivity of the organism of interest.
According to Mr Accuracy reports’s new survey, global Fermentation Engineering for Pharmaceutical Drugs market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Fermentation Engineering for Pharmaceutical Drugs market research.
In China, 5 largest manufacturers of Fermentation Engineering for Pharmaceutical Drugs are Changchun GeneScience Pharmaceutical, 3SBio Inc, Shanghai Fosun Pharmaceutical, Sichuan Kelun Pharmaceutical and Shanghai Shyndec Pharmaceutical, which make up over 15%. Among them, Changchun GeneScience Pharmaceutical is the leader with about 6% market share. In terms of product type, Monoclonal Antibodies occupy the largest share of the total market, about 54%. And in terms of product Application, the largest application is Hospital, followed by Clinic.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Fermentation Engineering for Pharmaceutical Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Changchun GeneScience Pharmaceutical
3SBio Inc
Shanghai Fosun Pharmaceutical
Sichuan Kelun Pharmaceutical
Shanghai Shyndec Pharmaceutical
CSPC Pharmaceutical Group
United Laboratories International Holdings
Tonghua Dongbao Pharmaceutical
Joincare Pharmaceutical Group
North China Pharma
Anhui Anke Biotechnology
Gan and Lee Pharmaceuticals
Shandong Kexing Bioproducts
Harbin Pharmaceutical Group
Segment by Type
Monoclonal Antibodies
Antibiotic
Insulin
Human Growth Hormone
Pharmaceutical Amino Acids
Others
Hospital
Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Fermentation Engineering for Pharmaceutical Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Fermentation Engineering for Pharmaceutical Drugs market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Fermentation Engineering for Pharmaceutical Drugs market research.
In China, 5 largest manufacturers of Fermentation Engineering for Pharmaceutical Drugs are Changchun GeneScience Pharmaceutical, 3SBio Inc, Shanghai Fosun Pharmaceutical, Sichuan Kelun Pharmaceutical and Shanghai Shyndec Pharmaceutical, which make up over 15%. Among them, Changchun GeneScience Pharmaceutical is the leader with about 6% market share. In terms of product type, Monoclonal Antibodies occupy the largest share of the total market, about 54%. And in terms of product Application, the largest application is Hospital, followed by Clinic.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Fermentation Engineering for Pharmaceutical Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company
Changchun GeneScience Pharmaceutical
3SBio Inc
Shanghai Fosun Pharmaceutical
Sichuan Kelun Pharmaceutical
Shanghai Shyndec Pharmaceutical
CSPC Pharmaceutical Group
United Laboratories International Holdings
Tonghua Dongbao Pharmaceutical
Joincare Pharmaceutical Group
North China Pharma
Anhui Anke Biotechnology
Gan and Lee Pharmaceuticals
Shandong Kexing Bioproducts
Harbin Pharmaceutical Group
Segment by Type
Monoclonal Antibodies
Antibiotic
Insulin
Human Growth Hormone
Pharmaceutical Amino Acids
Others
Segment by Application
Hospital
Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Fermentation Engineering for Pharmaceutical Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
